FDA Expands Approval of ZORYVE Cream 0.3% for Children as Young as 2 with Plaque Psoriasis

The FDA has expanded approval of ZORYVE Cream 0.3% for children as young as two years with plaque psoriasis. Learn about the benefits, clinical evidence, safety profile, and what this means for pediatric care.

The U.S. Food and Drug Administration (FDA) has approved an expanded indication for ZORYVE® (roflumilast) Cream 0.3%, allowing its use in children as young as two years old with plaque psoriasis. The approval represents an important advancement in pediatric dermatology by providing families and healthcare providers with a once daily, steroid free treatment option that can be used on all affected areas of the body.

Developed by Arcutis Biotherapeutics, ZORYVE Cream 0.3% is already approved for older children and adults with plaque psoriasis. The latest FDA decision extends its availability to younger patients, addressing a significant gap in long term treatment options for children living with this chronic inflammatory skin condition.

What Is Plaque Psoriasis?

Plaque psoriasis is a long lasting autoimmune skin disorder that causes skin cells to multiply faster than normal. This results in thick, raised patches covered with silvery scales. The condition often causes itching, discomfort, redness, and inflammation.

Although psoriasis is commonly associated with adults, it can begin during early childhood. Young children may develop plaques on the scalp, elbows, knees, face, skin folds, and other sensitive areas. Living with plaque psoriasis at a young age can affect sleep, daily activities, emotional wellbeing, and overall quality of life.

Because the disease is chronic, many children require ongoing treatment to manage symptoms and prevent flare ups.

Why This FDA Approval Matters

Until now, treatment choices for children under six years old have been relatively limited. Topical corticosteroids are commonly prescribed, but prolonged use may not be suitable for delicate areas such as the face, neck, groin, or skin folds.

The FDA approval of ZORYVE Cream 0.3% provides an alternative that is free from steroids while maintaining strong efficacy and a favorable safety profile. The cream can be applied once daily and does not carry restrictions on treatment duration, making it an attractive option for long term disease management.

This approval offers physicians greater flexibility when developing individualized treatment plans for pediatric patients.

Clinical Studies Supported the Decision

The FDA based its approval on data from clinical studies involving children aged two to five years with plaque psoriasis.

Researchers evaluated several important outcomes, including:

• Safety
• Drug absorption
• Tolerability
• Treatment effectiveness

Results demonstrated that ZORYVE Cream 0.3% performed consistently with findings from previous studies involving adolescents and adults. Most participants experienced improvements in psoriasis symptoms while maintaining a favorable safety profile.

Additional long term extension studies also supported the medication's use for up to 24 weeks, providing valuable information regarding continued treatment in younger children.

Benefits of ZORYVE Cream 0.3%

The expanded approval highlights several advantages of this topical treatment.

Steroid Free Formula

Unlike topical corticosteroids, ZORYVE Cream does not rely on steroids to reduce inflammation. This makes it particularly useful for patients requiring extended treatment or application on sensitive skin.

Once Daily Application

The cream requires only one application each day, which may improve treatment adherence among children and caregivers.

Suitable for Sensitive Areas

The product can be safely used on multiple body areas, including skin folds where traditional topical steroids are often used cautiously.

Long Term Use

Current labeling allows continued treatment without the duration limitations that often accompany steroid based therapies.

How ZORYVE Works

ZORYVE contains roflumilast, a phosphodiesterase 4 (PDE4) inhibitor.

PDE4 is an enzyme involved in the body's inflammatory response. By blocking this enzyme, roflumilast helps reduce the production of inflammatory chemicals that contribute to psoriasis symptoms.

As inflammation decreases, patients may experience improvements in redness, scaling, itching, and plaque thickness.

Safety Information

Like all prescription medications, ZORYVE may cause side effects.

Some commonly reported adverse reactions include:

• Diarrhea
• Headache
• Nausea
• Insomnia
• Mild application site discomfort
• Upper respiratory infections

The medication should not be used in patients with moderate to severe liver impairment. Patients and caregivers should discuss their complete medical history with their healthcare provider before starting treatment.

Healthcare professionals should also provide guidance on proper application techniques to maximize benefits and reduce unnecessary exposure.

Impact on Pediatric Dermatology

Dermatologists have welcomed the FDA's decision because it expands access to an evidence based treatment specifically studied in younger children.

Parents often face challenges balancing symptom control with concerns about long term steroid exposure. A targeted topical therapy that is approved for extended use may help improve disease management while reducing treatment related anxiety.

The approval also reflects growing progress in developing therapies specifically designed for pediatric dermatology rather than adapting adult treatments for younger patients.

Looking Ahead

The expanded approval of ZORYVE Cream 0.3% marks another milestone in psoriasis treatment. As research continues, physicians hope that additional targeted therapies will further improve outcomes for children living with chronic inflammatory skin diseases.

For families affected by pediatric plaque psoriasis, the availability of another FDA approved treatment option offers renewed optimism and greater flexibility in managing this lifelong condition.

Frequently Asked Questions

What is ZORYVE Cream 0.3%?

It is a prescription topical medication containing roflumilast, a PDE4 inhibitor used to treat plaque psoriasis.

Who can use ZORYVE Cream?

The FDA has approved ZORYVE Cream 0.3% for adults and children aged two years and older with plaque psoriasis.

Is ZORYVE a steroid?

No. ZORYVE is a steroid free topical treatment.

Can it be used on sensitive skin?

Yes. The cream is approved for use on all affected body areas, including sensitive skin folds.

How often is it applied?

The recommended dosing is once daily unless otherwise directed by a healthcare provider.

Conclusion

The FDA's expanded approval of ZORYVE Cream 0.3% provides an important new treatment option for children as young as two years with plaque psoriasis. By offering a once daily, steroid free therapy that has demonstrated safety and effectiveness in clinical studies, this approval helps address a longstanding need in pediatric dermatology. As more targeted treatments become available, children with chronic inflammatory skin diseases may benefit from improved symptom control and better quality of life.

Source

Arcutis Biotherapeutics. "FDA Approves ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children as Young as Age 2." Official company press release, June 29, 2026.

Medical Disclaimer

This article is intended for informational and educational purposes only. It should not be considered medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional before starting, stopping, or changing any medication or treatment plan. Medication approvals, indications, and prescribing information may change over time. Refer to the official prescribing information and your healthcare provider for the most current guidance.